AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
AENEAS：一项随机III期试验，比较奥莫替尼与吉非替尼作为一线疗法治疗伴有EGFR 19号外显子缺失或L858R突变的局部晚期或转移性非小细胞肺癌的疗效
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.02641
Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Jie, Weng; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Sun, Changan; Wei, Hongying; Li, Chuan; Ali, Siraj M; Miller, Vincent A; Wu, Qiong
